Rein Therapeutics
RNTX
29 hedge funds and large institutions have $4.65M invested in Rein Therapeutics in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.
613% more capital invested
Capital invested by funds: $652K → $4.65M (+$4M)
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
45% more funds holding
Funds holding: 20 → 29 (+9)
0.16% more ownership
Funds ownership: 0.35% → 0.52% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$739K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$367K |
| 3 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$326K |
| 4 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$81.5K |
| 5 |
Squarepoint
New York
|
+$77.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$53.3K |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
-$24.4K |
| 3 |
BlackRock
New York
|
-$15K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
RNTX Hedge Fund Activity: Q2 2020 in Review
29 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2020, worth a combined $4.65M — up 613% from $652K a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RNTX positions and 3 closed out — a net gain of 10 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $739K. The largest seller was William Blair & Company, cutting an estimated $53.3K.
- 29 institutional investors held Rein Therapeutics (RNTX) as of Q2 2020, up from 20 in Q1 2020.
- Funds reported $4.65M of Rein Therapeutics stock for Q2 2020, up 613% quarter-over-quarter.
- 13 funds opened new Rein Therapeutics positions in Q2 2020 and 3 closed out, a net change of +10 holders.
- The largest Rein Therapeutics buyer in Q2 2020 was Renaissance Technologies, an estimated $739K added.
- The largest Rein Therapeutics seller in Q2 2020 was William Blair & Company, an estimated $53.3K sold.
Based on aggregated 13F filings for Q2 2020.